KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Retained Earnings (2017 - 2026)

Moderna (MRNA) has disclosed Retained Earnings for 10 consecutive years, with $5.9 billion as the latest value for Q1 2026.

  • For Q1 2026, Retained Earnings fell 35.2% year-over-year to $5.9 billion; the TTM value through Mar 2026 reached $5.9 billion, down 35.2%, while the annual FY2025 figure was $45.0 million, 550.0% up from the prior year.
  • Retained Earnings hit $5.9 billion in Q1 2026 for Moderna, up from $45.0 million in the prior quarter.
  • Across five years, Retained Earnings topped out at $18.4 billion in Q1 2023 and bottomed at -$370.0 million in Q4 2022.
  • Average Retained Earnings over 5 years is $6.7 billion, with a median of $5.9 billion recorded in 2026.
  • On a YoY basis, Retained Earnings climbed as much as 98725.0% in 2022 and fell as far as 103.72% in 2022.
  • Moderna's Retained Earnings stood at -$370.0 million in 2022, then soared by 3777.3% to $13.6 billion in 2023, then tumbled by 100.07% to -$10.0 million in 2024, then skyrocketed by 550.0% to $45.0 million in 2025, then soared by 12966.67% to $5.9 billion in 2026.
  • According to Business Quant data, Retained Earnings over the past three periods came in at $5.9 billion, $45.0 million, and $27.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.